Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.86 USD

28.86
12,948,956

-0.23 (-0.79%)

Updated Sep 30, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID

by Zacks Equity Research

The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.

Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider

by Zacks Equity Research

Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.

Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.

Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates

by Zacks Equity Research

Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk

by Zacks Equity Research

J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

by Zacks Equity Research

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track

by Zacks Equity Research

Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.

Fed's Crucial FOMC Meeting in Focus

by Zacks Equity Research

Fed's Crucial FOMC Meeting in Focus.

Mark Vickery headshot

Amid a Big Week for the U.S. Economy, PFE, BP, EL Report

by Mark Vickery

Ahead of today's opening bell, we're in the green again, but only dipping a toe in the water just yet.

Pfizer (PFE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of -2.41% and 3.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

by Zacks Equity Research

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

by Zacks Equity Research

Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.

Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

by Kinjel Shah

Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

AbbVie (ABBV) Tops Q1 Earnings Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.